Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Memorial Sloan Kettering Cancer Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1681
Shown on this page
12
Current sort
Recently updated
Campus scope
Memorial Sloan Kettering Cancer Center, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Memorial Sloan Kettering Cancer Center, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 661–672 of 1,681 matching trials with a site at Memorial Sloan Kettering Cancer Center, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

NCT03533582
Site status not listed — check the official record
View directory record Official record
Conditions
Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Patient Observation, Resection, Sorafenib, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
180
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Recruiting Phase 2 Interventional

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

NCT06111781
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix 120 MG [Orgovyx], SBRT standard of care radiotherapy treatment
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
New Haven, Connecticut • Lebanon, New Hampshire • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Active, not recruiting Not applicable Interventional Results available

SP Thoracic IDE Study

NCT05150210
Site status not listed — check the official record
View directory record Official record
Conditions
Primary Lung Cancer, Benign Lung Disease, Thymoma, Myasthenia Gravis
Interventions
Robotic-Assisted Surgery
Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Active, not recruiting Phase 2 Interventional

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

NCT03493425
Site status not listed — check the official record
View directory record Official record
Conditions
Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7
Interventions
Carboplatin, Cisplatin, Docetaxel, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Questionnaire Administration, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
154
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Palo Alto, California + 111 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Active, not recruiting Phase 2 Interventional

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

NCT04438824
Site status not listed — check the official record
View directory record Official record
Conditions
Well-differentiated/Dedifferentiated Liposarcoma
Interventions
INCMGA00012, Palbociclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Active, not recruiting Phase 3 Interventional

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455
Site status not listed — check the official record
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
262
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

NCT07818018
Status at this site: Recruiting
View directory record Official record
Conditions
Esophageal Cancer, Advanced Esophageal Cancer, Gastric Cancer, Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Cancer
Interventions
Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Recruiting Phase 1 Interventional

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

NCT06246968
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma
Interventions
Pembrolizumab, Cryoablation, Histotripsy
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Recruiting No phase listed Observational

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

NCT06486454
Status at this site: Recruiting
View directory record Official record
Conditions
Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver, Benign Liver Tumor
Interventions
HistoSonics Edison System
Device
Lead sponsor
HistoSonics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
33
States / cities
Fullerton, California • Los Angeles, California • Mission Viejo, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Active, not recruiting Phase 3 Interventional

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080
Site status not listed — check the official record
View directory record Official record
Conditions
Large B-Cell Lymphoma
Interventions
Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
60
States / cities
Anchorage, Alaska • Anaheim, California • Clovis, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

NCT04201457
Site status not listed — check the official record
View directory record Official record
Conditions
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
Interventions
Dabrafenib, Trametinib, Hydroxychloroquine
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 30 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 5, 2026, 12:06 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810
Site status not listed — check the official record
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Interventions
Epcoritamab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
70
States / cities
Mobile, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 5, 2026, 12:06 AM EST

About this Memorial Sloan Kettering Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Memorial Sloan Kettering Cancer Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Memorial Sloan Kettering Cancer Center at any site, browse by condition, or browse by U.S. city.